156 related articles for article (PubMed ID: 38077371)
1. Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis.
Luo C; Chen H; Wu H; Liu Y; Li G; Lun W
Front Immunol; 2023; 14():1298902. PubMed ID: 38077371
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.
Sun H; Bu F; Li L; Zhang X; Xin X; Yan J; Huang T
Ann Pharmacother; 2024 Apr; 58(4):349-359. PubMed ID: 37488978
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Wang FH; Wei XL; Feng J; Li Q; Xu N; Hu XC; Liao W; Jiang Y; Lin XY; Zhang QY; Yuan XL; Huang HX; Chen Y; Dai GH; Shi JH; Shen L; Yang SJ; Shu YQ; Liu YP; Wang W; Wu H; Feng H; Yao S; Xu RH
J Clin Oncol; 2021 Mar; 39(7):704-712. PubMed ID: 33492986
[TBL] [Abstract][Full Text] [Related]
4. Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis.
Franklin C; Rooms I; Fiedler M; Reis H; Milsch L; Herz S; Livingstone E; Zimmer L; Schmid KW; Dittmer U; Schadendorf D; Schilling B
Eur J Cancer; 2017 Nov; 86():248-256. PubMed ID: 29055840
[TBL] [Abstract][Full Text] [Related]
5. Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells.
Rajasekaran N; Wang X; Ravindranathan S; Chin DJ; Tseng SY; Klakamp SL; Widmann K; Kapoor VN; Vexler V; Keegan P; Yao S; LaVallee T; Khare SD
Cancer Immunol Immunother; 2024 Feb; 73(3):60. PubMed ID: 38400933
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab plus capecitabine in the treatment of patients with residual nasopharyngeal carcinoma: a single-arm phase 2 trial.
Cao X; Huang HY; Liang CX; Lin ZC; Zhou JY; Chen X; Huang YY; Zhan ZJ; Ke LR; Han LJ; Xia WX; Tang LQ; Guo SS; Liang H; Guo X; Lv X
Nat Commun; 2024 Jan; 15(1):949. PubMed ID: 38297016
[TBL] [Abstract][Full Text] [Related]
7. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi Y; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Wang S; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Luo X; Wang X; Tang X; Feng H; Yao S; Keegan P; Xu RH
JAMA; 2023 Nov; 330(20):1961-1970. PubMed ID: 38015220
[TBL] [Abstract][Full Text] [Related]
8. CMV coinfection in treatment refractory immune checkpoint inhibitor colitis.
Harris KB; Funchain P; Baggott BB
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32434876
[TBL] [Abstract][Full Text] [Related]
9. A case of perforated immune-related colitis complicated by cytomegalovirus infection during treatment of immune-related adverse effect in lung cancer immunotherapy.
Nakai M; Kai Y; Suzuki K; Matsuda M; Kikukawa S; Masuda H; Soga M; Ueda T; Yoshimura A; Takano M; Hontsu S; Uno K; Muro S
Respir Med Case Rep; 2023; 41():101794. PubMed ID: 36583058
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of sequential chemoradiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma: A phase II trial.
Chen SY; Duan XT; Li HF; Peng L; Wang ZQ; Xu GQ; Hua YJ; Zou X; You R; Ouyang YF; Liu YP; Gu CM; Yang Q; Jiang R; Zhang MX; Lin M; Xie YL; Lin C; Ding X; Xie RQ; Duan CY; Zhang WJ; Huang PY; Chen MY
Cell Rep Med; 2023 Nov; 4(11):101279. PubMed ID: 37951218
[TBL] [Abstract][Full Text] [Related]
11. An unusual case of immune-related gastritis in one patient receiving toripalimab therapy.
Chen X; Shi W
Immunotherapy; 2023 Apr; 15(5):335-342. PubMed ID: 36852424
[TBL] [Abstract][Full Text] [Related]
12. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events.
Poto R; Troiani T; Criscuolo G; Marone G; Ciardiello F; Tocchetti CG; Varricchi G
Front Immunol; 2022; 13():804597. PubMed ID: 35432346
[TBL] [Abstract][Full Text] [Related]
13. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Mai HQ; Chen QY; Chen D; Hu C; Yang K; Wen J; Li J; Shi YR; Jin F; Xu R; Pan J; Qu S; Li P; Hu C; Liu YC; Jiang Y; He X; Wang HM; Lim WT; Liao W; He X; Chen X; Liu Z; Yuan X; Li Q; Lin X; Jing S; Chen Y; Lu Y; Hsieh CY; Yang MH; Yen CJ; Samol J; Feng H; Yao S; Keegan P; Xu RH
Nat Med; 2021 Sep; 27(9):1536-1543. PubMed ID: 34341578
[TBL] [Abstract][Full Text] [Related]
14. Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
Lin J; Xue M; Gao M; Yu P; Han S
Dermatol Ther (Heidelb); 2020 Aug; 10(4):863-867. PubMed ID: 32445174
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibition in first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A CAPTAIN-1st and JUPITER-02 trial-based cost-effectiveness analysis.
Tian K; Han J; Wang Z; Chen J
Oral Oncol; 2022 May; 128():105842. PubMed ID: 35428025
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis.
Furuta Y; Miyamoto H; Naoe H; Shimoda M; Hinokuma Y; Miyamura T; Miyashita A; Fukushima S; Tanaka M; Sasaki Y
Case Rep Gastroenterol; 2020; 14(1):103-109. PubMed ID: 32231510
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
Wei XL; Ren C; Wang FH; Zhang Y; Zhao HY; Zou BY; Wang ZQ; Qiu MZ; Zhang DS; Luo HY; Wang F; Yao S; Xu RH
Cancer Commun (Lond); 2020 Aug; 40(8):345-354. PubMed ID: 32589350
[TBL] [Abstract][Full Text] [Related]
18. Toripalimab (Loqtorzi) for nasopharyngeal carcinoma.
Med Lett Drugs Ther; 2024 Jan; 66(1694):e16-e17. PubMed ID: 38212260
[No Abstract] [Full Text] [Related]
19. Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab.
Zhou H; Xie X; Zhang T; Yang M; Zhou D; Yang T
Front Immunol; 2022; 13():850540. PubMed ID: 35401563
[TBL] [Abstract][Full Text] [Related]
20. Stuttering as a signal of encephalopathy associated with toripalimab in a pancreatic ductal adenocarcinoma patient: a case report.
He J; Chen X; Cheng K; Lv W; Cao D; Li Z
BMC Neurol; 2023 Mar; 23(1):96. PubMed ID: 36870985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
